California State Teachers Retirement System Reduces Position in Natus Medical Inc (BABY)

California State Teachers Retirement System reduced its position in shares of Natus Medical Inc (NASDAQ:BABY) by 7.2% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 48,130 shares of the medical equipment provider’s stock after selling 3,755 shares during the period. California State Teachers Retirement System’s holdings in Natus Medical were worth $1,839,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of BABY. Cambiar Investors LLC acquired a new stake in shares of Natus Medical during the 4th quarter valued at approximately $8,970,000. WCM Investment Management CA raised its position in shares of Natus Medical by 503.8% during the 4th quarter. WCM Investment Management CA now owns 267,850 shares of the medical equipment provider’s stock valued at $10,232,000 after acquiring an additional 223,490 shares in the last quarter. Renaissance Technologies LLC acquired a new stake in shares of Natus Medical during the 4th quarter valued at approximately $6,733,000. Deutsche Bank AG increased its position in Natus Medical by 435.2% in the fourth quarter. Deutsche Bank AG now owns 162,001 shares of the medical equipment provider’s stock worth $6,186,000 after buying an additional 131,730 shares during the period. Finally, Dimensional Fund Advisors LP increased its position in Natus Medical by 3.3% in the third quarter. Dimensional Fund Advisors LP now owns 1,604,876 shares of the medical equipment provider’s stock worth $60,183,000 after buying an additional 51,938 shares during the period. 95.96% of the stock is currently owned by institutional investors and hedge funds.

How to Become a New Pot Stock Millionaire

In other Natus Medical news, Director Ken Ludlum sold 4,000 shares of the stock in a transaction on Friday, March 2nd. The stock was sold at an average price of $31.68, for a total value of $126,720.00. Following the sale, the director now directly owns 93,825 shares of the company’s stock, valued at $2,972,376. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 5.50% of the stock is owned by company insiders.

BABY has been the topic of several analyst reports. Roth Capital set a $39.00 target price on Natus Medical and gave the stock a “buy” rating in a research report on Tuesday, February 27th. Benchmark reaffirmed a “buy” rating and issued a $49.00 target price (down from $55.00) on shares of Natus Medical in a research report on Tuesday, January 16th. BidaskClub raised Natus Medical from a “sell” rating to a “hold” rating in a research report on Saturday, March 17th. Zacks Investment Research lowered Natus Medical from a “buy” rating to a “hold” rating in a research report on Tuesday, December 26th. Finally, William Blair lowered Natus Medical from an “outperform” rating to a “market perform” rating in a research report on Monday, January 8th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $44.33.

Shares of NASDAQ BABY opened at $32.80 on Friday. Natus Medical Inc has a 1-year low of $28.00 and a 1-year high of $43.60. The company has a current ratio of 3.32, a quick ratio of 2.54 and a debt-to-equity ratio of 0.37. The firm has a market capitalization of $1,107.56, a price-to-earnings ratio of 22.62 and a beta of 0.47.

Natus Medical (NASDAQ:BABY) last issued its earnings results on Wednesday, February 7th. The medical equipment provider reported $0.42 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.54 by ($0.12). Natus Medical had a positive return on equity of 11.36% and a negative net margin of 4.05%. The company had revenue of $131.40 million during the quarter, compared to analyst estimates of $131.38 million. During the same period in the prior year, the business earned $0.51 earnings per share. Natus Medical’s quarterly revenue was up 22.0% on a year-over-year basis. sell-side analysts anticipate that Natus Medical Inc will post 1.63 EPS for the current fiscal year.

Natus Medical declared that its board has initiated a stock buyback program on Thursday, February 22nd that allows the company to repurchase $30.00 million in shares. This repurchase authorization allows the medical equipment provider to buy shares of its stock through open market purchases. Shares repurchase programs are typically an indication that the company’s board believes its stock is undervalued.

COPYRIGHT VIOLATION NOTICE: This story was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this story on another publication, it was stolen and republished in violation of United States & international trademark & copyright laws. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2018/04/07/california-state-teachers-retirement-system-reduces-position-in-natus-medical-inc-baby.html.

About Natus Medical

Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.

Want to see what other hedge funds are holding BABY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natus Medical Inc (NASDAQ:BABY).

Institutional Ownership by Quarter for Natus Medical (NASDAQ:BABY)

Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply